Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Galderma Delivers Record Sales of $2.4 Billion in H1 2025 - Happi
Financial News

Galderma Delivers Record Sales of $2.4 Billion in H1 2025

Results reflect the company’s aim to become a true ‘powerhouse in dermatology,’ says CEO.

Galderma CEO Flemming Ørnskov and President, US, Heather Wallace.

Galderma Group AG, a dermatology category leader, delivered record net sales of $2.448 Billion for the first half of 2025, officials said.

The gain represents net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix. The increase reflects double-digit growth in both international markets and the US, with strong performance across all product categories, including year-on-year growth of 9.8% for injectable aesthetics, 7.7% for dermatological skincare and 26.9% for therapeutic dermatology at constant currency.

“Galderma’s strong performance in the first half of 2025 underscores the impact of our executional excellence across product categories and the continued ramp-up of our two potential blockbuster launches, Nemluvio and Relfydess,” said Galderma CEO Flemming rnskov. “Reflecting this strong progress and confidence in the business, we are raising our full-year guidance on net sales. With the establishment of our new US headquarters in Miami and sustained scientific momentum, we are also sharpening our focus – accelerating growth and moving from category leadership to becoming a true powerhouse in dermatology.”

Significant progress has been made on the launch of innovation, including Nemluvio, which continues to outperform, delivering $131 million in sales, the ongoing positive uptake of Relfydess now launched in 17 markets, and geographic expansion in fillers and biostimulators.

The company experienced growth in core EBITDA, delivering $555 million, up 9.5% year-on-year at constant currency, with a slightly higher than expected core EBITDA margin for the first half of 22.7%.

Raising 2025 full-year guidance on net sales, the company expects growth of 12-14% at constant currency (previously 10-12%) and confirming guidance on core EBITDA margin of approximately 23% at constant currency.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters